MX2016015574A - Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b. - Google Patents

Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.

Info

Publication number
MX2016015574A
MX2016015574A MX2016015574A MX2016015574A MX2016015574A MX 2016015574 A MX2016015574 A MX 2016015574A MX 2016015574 A MX2016015574 A MX 2016015574A MX 2016015574 A MX2016015574 A MX 2016015574A MX 2016015574 A MX2016015574 A MX 2016015574A
Authority
MX
Mexico
Prior art keywords
proteins
cells
virus
ivig
blood plasma
Prior art date
Application number
MX2016015574A
Other languages
English (en)
Spanish (es)
Inventor
Hoang Kieu
Original Assignee
Rare Antibody Antigen Supply Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rare Antibody Antigen Supply Inc filed Critical Rare Antibody Antigen Supply Inc
Publication of MX2016015574A publication Critical patent/MX2016015574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016015574A 2014-05-28 2015-05-28 Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b. MX2016015574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (1)

Publication Number Publication Date
MX2016015574A true MX2016015574A (es) 2018-05-28

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015574A MX2016015574A (es) 2014-05-28 2015-05-28 Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.

Country Status (10)

Country Link
EP (1) EP3148574B1 (enExample)
JP (1) JP2017525752A (enExample)
CN (1) CN107106664A (enExample)
AU (1) AU2015266997A1 (enExample)
BR (1) BR112016027818A2 (enExample)
CA (1) CA2949994A1 (enExample)
ES (1) ES2878043T3 (enExample)
MX (1) MX2016015574A (enExample)
RU (1) RU2016151761A (enExample)
WO (1) WO2015184050A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106664A (zh) 2014-05-28 2017-08-29 美国稀有抗体抗原供应公司 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
CN118878610B (zh) * 2024-03-19 2025-09-02 北京达尔文细胞生物科技有限公司 一种蛋白聚合物及其生产工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) * 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
KR20130070576A (ko) * 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
MX2012013233A (es) * 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
TW201335181A (zh) 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
CN107106664A (zh) 2014-05-28 2017-08-29 美国稀有抗体抗原供应公司 用于调节淋巴细胞和治疗乙型肝炎病毒的ivig蛋白和kh蛋白的纯化组合物

Also Published As

Publication number Publication date
BR112016027818A2 (pt) 2017-10-24
JP2017525752A (ja) 2017-09-07
EP3148574A1 (en) 2017-04-05
RU2016151761A (ru) 2018-07-03
EP3148574A4 (en) 2017-04-05
WO2015184050A1 (en) 2015-12-03
ES2878043T3 (es) 2021-11-18
CN107106664A (zh) 2017-08-29
RU2016151761A3 (enExample) 2018-12-26
CA2949994A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
AU2015266997A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
MX2025001503A (es) Medios y metodo para preparar vectores virales y usos de los mismos
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
NZ730803A (en) Methods for the preparation of ribosides
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2022007522A (es) Anticuerpos anti-cd27.
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX2022001105A (es) Anticuerpos anti tigit.
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX379275B (es) Polvo de coleopteros.
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX2019002699A (es) Terapia genica para pacientes con anemia de fanconi.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12022550771A1 (en) Antibodies to tigit
TW201613636A (en) Methods of treating Alzheimer's Disease
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
BR112016027818A2 (pt) composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.